Lifeboat Foundation

In a study in Nature Plants, Yiping Qi, associate professor of Plant Science at the University of Maryland (UMD), introduces a new and improved CRISPR 3.0 system in plants, focusing on gene activation instead of traditional gene editing. This third generation CRISPR system focuses on multiplexed gene activation, meaning that it can boost the function of multiple genes simultaneously. According to the researchers, this system boasts four to six times the activation capacity of current state-of-the-art CRISPR technology, demonstrating high accuracy and efficiency in up to seven genes at once. While CRISPR is more often known for its gene editing capabilities that can knock out genes that are undesirable, activating genes to gain functionality is essential to creating better plants and crops for the future.

“While my lab has produced systems for simultaneous gene editing [multiplexed editing] before, editing is mostly about generating loss of function to improve the crop,” explains Qi. “But if you think about it, that strategy is finite, because there aren’t endless genes that you can turn off and actually still gain something valuable. Logically, it is a very limited way to engineer and breed better traits, whereas the plant may have already evolved to have different pathways, defense mechanisms, and traits that just need a boost. Through activation, you can really uplift pathways or enhance existing capacity, even achieve a novel function. Instead of shutting things down, you can take advantage of the functionality already there in the genome and enhance what you know is useful.”

In his new paper, Qi and his team validated the CRISPR 3.0 system in rice, tomatoes, and Arabidopsis (the most popular model plant species, commonly known as rockcress). The team showed that it is possible to simultaneously activate many kinds of genes, including faster flowering to speed up the breeding process. But this is just one of the many advantages of multiplexed activation, says Qi.

Circa 2018

CRISPR will realize its potential in plastic and reconstructive surgery only if plastic surgeons gain familiarity with this disruptive technology and become active contributors and leaders in applying CRISPR to their respective areas of expertise.

A once forgotten technology, RNA editing has been gaining traction as a treatment for genetic conditions given its key advantages over CRISPR gene editing.

Since CRISPR-Cas9 gene editing was first reported in 2012, its promise of making gene editing faster, cheaper, and easier than ever before led to an explosion in the number of publications referring to this gene editing technology.

An increasing number of research labs and companies are aiming to translate CRISPR gene editing into therapies for genetic diseases. However, further research has unveiled that there are more limitations to using CRISPR-Cas9 to cure diseases than initially expected. For example, the technology has been reported to introduce off-target changes to the DNA, raising concerns about its safety.

Novel study designed to correct genetic abnormalities of red blood cells.

Cleveland Clinic researchers are enrolling patients in a clinical trial that aims to work toward a cure for sickle cell disease, by changing the patient’s genetics. Sickle cell disease, a genetic blood disorder, is a painful and debilitating condition for which there are few approved therapies.

The multicenter study will evaluate the safety and effectiveness of a single dose of EDIT-301, an experimental one-time gene editing cell therapy that modifies a patient’s own blood-forming stem cells to correct the mutation responsible for sickle cell disease.

Continue reading “Cleveland Clinic Trial to Test Gene Therapy as Treatment of Sickle Cell Disease” »

There are now several monoclonal antibodies, identical copies of a therapeutic antibody produced in large numbers, that are authorized for the treatment of COVID-19. But in the ongoing effort to beat this terrible pandemic, there’s plenty of room for continued improvements in treating infections with SARS-CoV-2, the virus that causes COVID-19.

With this in mind, I’m pleased to share progress in the development of a specially engineered therapeutic antibody that could be delivered through a nasal spray. Preclinical studies also suggest it may work even better than existing antibody treatments to fight COVID-19, especially now that new SARS-CoV-2 “variants of concern” have become increasingly prevalent.

These findings come from Zhiqiang An, The University of Texas Health Science Center at Houston, and Pei-Yong Shi, The University of Texas Medical Branch at Galveston, and their colleagues. The NIH-supported team recognized that the monoclonal antibodies currently in use all require time-consuming, intravenous infusion at high doses, which has limited their use. Furthermore, because they are delivered through the bloodstream, they aren’t able to reach directly the primary sites of viral infection in the nasal passages and lungs. With the emergence of new SARS-CoV-2 variants, there’s also growing evidence that some of those therapeutic antibodies are becoming less effective in targeting the virus.-Dr Francis Collins.

In America, at least 17 people a day die waiting for an organ transplant. But instead of waiting for a donor to die, what if we could someday grow our own organs?

Last week, six years after NASA announced its Vascular Tissue Challenge, a competition designed to accelerate research that could someday lead to artificial organs, the agency named two winning teams. The challenge required teams to create thick, vascularized human organ tissue that could survive for 30 days.

The two teams, named Winston and WFIRM, both from the Wake Forest Institute for Regenerative Medicine, used different 3D-printing techniques to create lab-grown liver tissue that would satisfy all of NASA’s requirements and maintain their function.

Continue reading “NASA inches closer to printing artificial organs in space” »

But now a spy swims among them: Mesobot. Today in the journal Science Robotics, a team of engineers and oceanographers describes how they got a new autonomous underwater vehicle to lock onto movements of organisms and follow them around the ocean’s “twilight zone,” a chronically understudied band between 650 feet and 3200 feet deep, which scientists also refer to as mid-water. Thanks to some clever engineering, the researchers did so without flustering these highly sensitive animals, making Mesobot a groundbreaking new tool for oceanographers.

“It’s super cool from an engineering standpoint,” says Northeastern University roboticist Hanumant Singh, who develops ocean robots but wasn’t involved in this research. “It’s really an amazing piece of work, in terms of looking at an area that’s unexplored in the ocean.”

Mesobot looks like a giant yellow-and-black AirPods case, only it’s rather more waterproof and weighs 550 pounds. It can operate with a fiber-optic tether attached to a research vessel at the surface, or it can swim around freely.

Check out my short video in which I explain some super exciting research in the area of nanotechnology: de novo protein lattices! I specifically discuss a journal article by Ben-Sasson et al. titled “Design of biologically active binary protein 2D materials”.

Here, I explain an exciting nanotechnology paper “Design of biologically active binary protein 2D materials” (https://doi.org/10.1038/s41586-020-03120-8).

Continue reading “Synthetic protein lattices explained” »

Circa 2020

Researchers at UC Berkeley have developed a rapid test for SARS-CoV-2 that uses an enzyme to cleave viral RNA, initiating a fluorescent signal that can be detected using a smartphone camera, and which can provide a quantitative measurement of the level of viral particles in the sample. The test produce a result in as little as 30 minutes and does not require bulky or expensive laboratory equipment.

Continue reading “CRISPR Test Uses Cell Phone Camera to Detect SARS-CoV-2” »